An immunotherapy approach to COVID-19

Coronavirus disease 2019 (COVID-19) is a virus-based illness brought on by SARS-CoV-2, a member of the Coronaviridae family that causes severe acute respiratory syndrome. The World Health Organization (WHO) declared the recently discovered, swiftly spreading epidemic to be a pandemic on March 11, 2020. Along with risk-reduction strategies like immunisation and physical and social seclusion, a variety of therapy techniques have been created with the goal of curing the disease. Regarding its function in eradicating the virus and in causing complications such cytokine storm syndrome, the immune system is characterised as a double-edged sword in the pathophysiology of COVID-19. As a result, immune-based therapeutic strategies, such as corticosteroids, Intravenous Immunoglobulins (IVIG), interferon therapy, and more COVID-19-specific strategies like anti-SARS-CoV-2-monoclonal antibodies, have emerged as an intriguing area of COVID-19 study.